▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1975 by analyst upside · 2026-06-27
QURE
uniQure N.V.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+29.7%
implied upside to consensus target
Current Price $47.51
Consensus Target $61.64
Bull Target $92.45
Bear Target $35.86
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
3
Sell
0
52-Week Low $8.73
52-Week High $71.5
YTD Return +103.1%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E -16.2x
EPS (TTM) $-3.49
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $18M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.73
52-Week High $71.5
Current Price $47.51
Bear Target $35.86
Bull Target $92.45
● Now $47.51 ● Target $61.64
TRADING DATA
Avg Volume 2.1M
YTD Return +103.1%
Analyst Count 11
Consensus Buy
Upside to Target +29.7%
Last Updated 2026-06-27

ANALYST SUMMARY

uniQure N.V. (QURE) is currently trading at $47.51 with a Wall Street consensus price target of $61.64, implying potential upside of 29.7% over the next 12 months. 11 analysts currently cover QURE, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $92.45, while the most cautious has a target of $35.86.

QURE operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 103.1% year-to-date and is currently trading near the upper end of its 52-week range of $8.73 – $71.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

OPCH +31.0%
Option Care Health, Inc.
$3B · P/E 16.8x · Buy
DOCS +21.7%
Doximity, Inc.
$4B · P/E 20.3x · Buy
ACAD +25.0%
ACADIA Pharmaceuticals Inc.
$4B · P/E 11.5x · Buy
ITGR +3.9%
Integer Holdings Corporation
$3B · P/E 23.3x · Buy
PBH +35.2%
Prestige Consumer Healthcare Inc.
$2B · P/E 12.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for QURE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays ↑ Upgrade
Equal-Weight → Overweight 2026-06-18 Building track record
Goldman Sachs — Reiterated
Neutral → Neutral 2026-06-18 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-06-18 29% win rate (7 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-06-18 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-05-06 31% win rate (48 calls)
Chardan Capital — Reiterated
Buy → Buy 2026-04-30 33% win rate (6 calls)
Goldman Sachs — Reiterated
Neutral → Neutral 2026-04-20 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-03-23 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
39
out of 100
Coverage depth
19/30
Consensus clarity
6/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →